2020 Revenues ($USD) : $8,497,100,000
2020 R&D spend : $2,735,000,000
2020 Number of Employees : 9,123
Fiscal Year End : 12/31/2020
Key People : Leonard Schleifer, CEO and president

Regeneron Pharmaceuticals is a biotechnology company that commercializes medicines designed to treat patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and other rare diseases. The Tarrytown, N.Y.-based company commercializes eight medicines, with its Eylea injection leading sales in its most recent fiscal year. In November last year, Regeneron's antibody cocktail casirivimab and imdevimab received FDA emergency use authorization to treat mild to moderate COVID-19 in adults and pediatric patients at least 12 years of age and weighing at least 40 kg. –DK